Laboratorios Richmond SACIF
BCBA:RICH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
EIH Associated Hotels Ltd
NSE:EIHAHOTELS
|
IN |
|
F
|
Fujian Jinsen Forestry Co Ltd
SZSE:002679
|
CN |
|
Staidson Beijing BioPharmaceuticals Co Ltd
SZSE:300204
|
CN |
|
D
|
D P Abhushan Ltd
NSE:DPABHUSHAN
|
IN |
Laboratorios Richmond SACIF
Other Receivables
Laboratorios Richmond SACIF
Other Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Laboratorios Richmond SACIF
BCBA:RICH
|
Other Receivables
4.2B
|
CAGR 3-Years
59%
|
CAGR 5-Years
85%
|
CAGR 10-Years
N/A
|
|
Laboratorios Richmond SACIF
Glance View
Laboratorios Richmond SACIF manufactures pharmaceutical products. The company is headquartered in Buenos Aires, Buenos Aires. The company went IPO on 2017-12-22. The firm's product categories include: Antiviral, under the brands Ciganclor, Lazinevir, Leuzan, Mivuten, Probirase, Protease, Selmivir, Trivenz, Virontar, Virontar N, Virontar 600, Vuclodir, Zepril, Zetavudin, and Zetrotax; Oncologi and Oncohematologic, under the brands Bemux, Capecit, Doxetal, Drifen, Espasevit, Fontrax, Gezt, and Monofer, among others; Cardiovascular, under the brands Amze 5, Amze 10, Antiplaq, Bilip 10, Bilip 20, Tacardia, and Timezol 20, among others; Neuropsychiatric, under the brands Dalam 15, Dolofrix 10, Donepes 5, and Prilben 10, among others, as well as Hospital, under the brands Amidiaz, Dalam, and Fentax, among others.
See Also
What is Laboratorios Richmond SACIF's Other Receivables?
Other Receivables
4.2B
ARS
Based on the financial report for Dec 31, 2025, Laboratorios Richmond SACIF's Other Receivables amounts to 4.2B ARS.
What is Laboratorios Richmond SACIF's Other Receivables growth rate?
Other Receivables CAGR 5Y
85%
Over the last year, the Other Receivables growth was -1%. The average annual Other Receivables growth rates for Laboratorios Richmond SACIF have been 59% over the past three years , 85% over the past five years .
